

INTERNATIONAL CANCER IMAGING SOCIETY
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
28TH FEBRUARY 2022

Charity number 1082082
Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
28TH FEBRUARY 2022

Contents	Page
Report of the Trustees	1-9
Independent Examiner's Report	10
Statement of Financial Activities	11
Balance Sheet	12
Notes to the Accounts	13-16

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2022.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznick
Dr. Conor Collins
Dr. Leslie Quint (resigned 1 November 2021)
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Dr. Evis Sala
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Lucidarme
Dr. Thierry Huisman (appointed 1 November 2021)
Prof. Pek Lan Khong (appointed 1 November 2021)
Prof. Giuseppe Petralia (appointed 1 November 2021)

The key management personnel are the trustees and Maureen Watts - General Manager.

Secretary and Registered Office Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Bankers Barclays Bank plc
9 Portman Square
London
W1A 3AL

**Independent
Examiners** Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors Radcliffes Le Brasseur
5 Great College Street
Westminster
London
SW1P 3SJ

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

- a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
- b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
- c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
- d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects is through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Structure, Governance and Management

International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity and is governed by its memorandum and articles of association.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

Achievements and Performance

During the period under review the Trustees convened on two occasions, in March 2021 and in September 2021 for the Annual General Meeting. Both meetings were conducted online by virtual means due to the ongoing pandemic continuing to preclude travel and face to face meetings.

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in April, July, September and November 2021, and January 2022. These meetings were all conducted virtually enabling online participation of the internationally based Board members. The Secretariat comprises two part-time employees and two contracted staff who together maintain full and proper administrative control of all Society activities, to ensure the Society is running smoothly.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register introduced in 2020 is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk. A suite of Human Resources policies has been developed with input from an HR Consultant. The Terms of Reference of the Executive Board were reviewed to ensure these remain fit for purpose. Updates were agreed at the Trustees' AGM, in particular that four members may be elected to the Board (rather than three) and that at least five meetings per year should be held, rather than six, now that the Executive Board has been established for over 10 years.

The Chairmen of the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications report to each Executive Board meeting, providing the opportunity for regular review, to focus attention and encourage growth for key elements of Society activity.

Following cancellation of the annual teaching course in September 2020, it had been hoped to resume in-person meetings from 2021 but it remained evident that both the physical and financial risks would be too high. In March 2021 the Trustees agreed that all meetings should continue to be arranged as virtual meetings. This included the AI & Machine Learning course scheduled for May 2021, planned for Lisbon, Portugal, and the Annual Teaching Course in London deferred from 2020 to September 2021. In addition, it was agreed that all ICIS Interactive Masterclass workshops would be conducted online until confidence of being in a classroom setting had returned.

In the virtual setting, registrations for both the AI & Machine Learning course in May 2021 and the annual teaching course in September 2021 proved lower than anticipated, highlighting the level of competition from other organisations who had also migrated to online meetings in view of the pandemic, thereby creating a rather saturated market.

The ICIS Interactive Masterclass workshops however remained a very popular element of the Society's educational offering, and adoption of the online format for these courses proved very popular and successful. Five days' online masterclass workshops were held in 2021, maintaining a valuable income stream for the Society.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

During the Annual General Meeting in September 2021, the Trustees undertook a further review of the consequences of the pandemic and whilst a degree of uncertainty remained over the preferred format of teaching courses, it was agreed to plan the ICIS Interactive Imaging of Gynaecological Cancers workshop as a classroom course in January 2022.

By mid-December 2021, however, registrations for this course remained lower than would have been hoped, enquiries continued on the availability of this course online and the decision was taken to postpone the course and conduct it online in spring 2022, to attract a larger number of delegates and be sure of generating a surplus of income.

The series of bi-monthly webinars introduced in October 2020 have continued to generate substantial interest from a worldwide audience. The webinars are free to watch live and subsequently available in the ICIS members' area of the website. A range of topics is covered, often providing the opportunity to promote forthcoming ICIS Interactive workshops or other Society activities.

A further new initiative was undertaken in October 2021, 'Read with the Experts'. Registrants were given the opportunity to review cases in advance of online mentored review in a seminar style setting, with cases available for a further 72 hours after the sessions to allow personal review and reflection. The PACS platform of the corporate sponsor, INFINITT, was utilized and a partnership with Amazon Web Services (AWS) was secured for this event with sponsored provision of "cloud time". Registration was free of charge for participants, and the industry support enabled this event to be cost-neutral for the Society. Unfortunately, interest was very limited with a low number of registrants and post-event analytics demonstrated little uptake of this free facility. A review will be undertaken to assess the value of creating similar content in a renewed format to provide e-learning material for the Society.

A new opportunity was afforded in November 2021 to attend the Radiological Society of North America Annual Scientific Meeting (RSNA) with a complimentary Society booth, granted by the Board of RSNA following review of the Society's educational mission. RSNA is the world's largest radiological conference and this presented an opportunity to promote the Society, the Society journal '*Cancer Imaging*' and the forthcoming annual teaching course ICIS 2022 to be held in Boston.

ICIS satellite meetings have remained on hold during the period under review. Whilst considered an important part of the Society's educational output to reach and teach colleagues around the globe, the ongoing pandemic has necessitated a pause to satellite meeting activity.

Opportunities for improving international visibility of the Society are under constant review and ways to market our events worldwide. Social media tools are utilised to disseminate information, alongside mailings, advertising and the monthly e-newsletter. Regular social media activity is maintained through a range of platforms (Twitter, LinkedIn, Facebook, and YouTube) and the ICIS website is regularly updated to provide current and accurate information. Promoting the Society aims to increase membership, attendance at teaching courses and readership of '*Cancer Imaging*' with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

The Society continues to monitor its compliance with the General Data Protection Regulations (GDPR), through its registration with the Information Commissioner's Office and in line with the UK General Data Protection Regulation (UK GDPR 2018), tailored by the Data Protection Act 2018.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

'*Cancer Imaging*' continues to be published by BioMed Central as an online open access journal. The number of submissions fell during the period under review, similar to the decrease experienced by other journals. However, the journal's performance was not affected and in June 2021 the Impact Factor was announced at 3.909, the highest ever recorded in the journal's history. This increased '*Cancer Imaging*'s ranking amongst other Radiology and Oncology journals, and produced a 5-year IF of 3.849. Since securing the new contract with the publishers, close collaboration between the Editors-in-Chief and the editorial team has stimulated the journal's further growth and development.

Professor Rodney Hicks from the Peter MacCallum Cancer Centre, Melbourne, Australia, and Dr Annick Van den Abbeele from the Dana Farber Cancer Institute, Boston, USA, are Joint Honorary Editors-in-Chief, with Professor Stefan Diederich from the Marien Hospital Düsseldorf, Germany, as Deputy Editor. The Editorial Board works to develop the pool of submission reviewers able to take on this important work in a timely manner, whilst supporting the Editors-in-Chief with plans to develop '*Cancer Imaging*' further.

The number of Society members has remained lower since the onset of the pandemic. Numbers are generally boosted through registration to the annual teaching course and the knock-on effect of cancelling the 2020 annual course and the purely online delivery of the 2021 course, has reduced the number of people deciding to renew or take up membership of the Society.

One of the key membership benefits is reduced registration fees for Society teaching courses; other benefits include a 20% discount on the article processing charge for accepted publications in *Cancer Imaging*, and access to the members' area of the website with its expanding repository of recorded lectures and scientific posters. The Executive Board continues to review other possible elements to promote and enhance the appeal of joining the Society.

At 28 February 2022, the number of Society members was 146 representing 35 countries worldwide; the number of Fellows was 76 and one Associate Fellow, representing 19 countries.

Financial Review

The Trustees and the Executive Board continue to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. The ongoing impact of the pandemic cannot be underestimated. Following cancellation of the 2020 annual teaching course, migration of the 2021 annual teaching course to a fully virtual meeting resulted in a significantly reduced income for two successive years. The Trustees are conscious that the duration of the pandemic will prolong economic constraints and present an additional challenge when securing commercial sponsorship of future annual teaching courses, also potentially affecting the number of delegates registering.

Migration of the ICIS Interactive Masterclass series to an online setting proved a valuable source of income without which the burden placed on Society reserves would have been significantly higher. During the period under review, five online workshops were delivered, generating valuable income during this challenging time. In view of the excellent feedback to the online format, it is anticipated that online delivery of some courses will continue in the future, alongside a programme of classroom courses provided pandemic restrictions permit in-person attendance.

The webinar series has attracted attention from a widespread geographical audience and also some industry interest with sponsorship received from companies working within the webinar subject field. This support has proved very valuable to defray Society running expenses.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

Engagement of personnel continues with two-yearly renewable contracts to allow for appropriate review, including salaries. ICIS does not have a central office facility for personnel, thus overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters. Engagement within the international radiology community is under constant review and registration for teaching courses is closely monitored, securing income for the Society.

The Society's corporate sponsorship package is aimed at large companies who are willing to make a notable financial commitment to the Society. These sponsorship agreements facilitate robust financial planning and forecasting, are re-negotiated for each contract term, but have been adversely affected by the pandemic due to worldwide economic pressures.

Siemens Healthineers, a machine manufacturing company, have continued their support but at the slightly reduced level for this current period. Guerbet, a contrast media company, renewed their support, also at a lower level than in previous periods.

A new corporate sponsor, INFINITT, a South Korean PACS company, provided sponsorship for the 15-month period to December 2021, but declined to continue their support in 2022. It may be reconsidered in the future but was not deemed to fit within the company's current plan.

'Cancer Imaging' is a significant element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets have both proved a valuable additional income stream for the Society.

The option to apply a surcharge to the Article Processing Charges (APC) remains, the proceeds of which would provide direct additional income for the Society from each article published. However, it is important to be mindful of the potential impact this could have to limit the journal's attractiveness to authors or further reduce the number of submissions.

The Trustees are pleased to report that the overall outcome to the year ending 28 February 2022 shows an increase of Society reserves, placing the Society in a strengthened financial position despite the challenges faced during this financial period, and the substantial impact of the pandemic on the Society. This achievement has been possible due to the support secured from industry and income generated by online delivery of ICISi masterclass workshops, alongside the stringent approach to control of Society expenditure.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation to assure a long-term future for the Society.

Reserves Policy

The Society's policy is to strive to build and hold reserves sufficient to confidently plan to run at least two future annual teaching courses, our flagship event and significant income stream, and be able to provide cover for one failed teaching course. The Society had reserves of £357,740 that were not invested in fixed assets at the year end to February 2022; (2021: £318,468).

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees constantly strive to improve and expand the educational portfolio of the Society, reaching additional colleagues in the radiology community internationally and ensuring a stable financial future to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components to this strategy, in addition to attracting high levels of sponsorship, to generate sufficient income to offset the costs of the administrative structure and add to reserves. The pandemic has necessitated additional focus on careful review of future Society activity.

Whilst during 2021 there was a global shift to virtual meetings, an element of online fatigue has become apparent and a degree of desire for in-person meetings with networking opportunities has returned. The Executive Board has considered the balance of virtual against in-person meetings and decided that in-person meetings should be included in Society activities in 2022.

Discussions are underway with the Champalimaud Foundation to review the possibility of holding the third *ICIS in Focus* meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging in June 2022. The previous financial support provided by the Foundation will not be available due to the impact of the pandemic on Foundation reserves, but alternative funding arrangements are being considered.

The 2022 annual teaching course will be delivered in-person in Boston, Massachusetts, USA, 12-14 September 2022, the first annual course to be held outside the UK or Europe. It is hoped this will promote the Society, generate more interest and expand the membership in the USA. The theme of the meeting has been chosen as 'Cancer Imaging: An All-Inclusive Specialty' with the aim of engaging the radiological and nuclear medicine communities globally with coverage and input from all continents of the world over the course of the three-day meeting.

Consideration will be given in due course whether to include any hybrid element to this meeting but it is hoped that the opportunity to resume in-person meetings and networking with international colleagues will result in positive registrations. The meeting President has secured substantial industry support for the meeting which should provide a sound basis from which to deliver a financially successful event.

The President for the annual teaching course in 2023 is based in Paris, France. However, the intention is to hold this annual teaching course in London, utilising the deposit carried over at the British Museum from the cancellation of ICIS 2020. The Trustees are grateful to the British Museum administrators who have been very supportive in permitting this prolonged delay of three years.

Two new ICIS Interactive Masterclass workshops are being developed to expand the portfolio of topics covered. In February 2023 the workshop on head and neck tumours will be launched, with a new workshop on renal/adrenal tumours planned for later in 2023. For the initial delivery, these will be classroom courses, with the possibility to migrate online in the future.

Further plans include revision of the thoracic course, last held in 2018, and development of a second edition of the ever-popular whole-body MRI course. The possibility of a third edition prostate course or conducting the existing prostate course in Sweden is also under review.

Establishing an e-learning platform remains under review with the proposal to introduce self-directed e-learning modules. Material from retired first edition ICIS Interactive Masterclass courses will be adapted to create modules for independent learning. A charge will be levied for each module, thereby generating an additional income stream for the Society.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

The opportunity to resume in-person satellite meetings will be kept under review taking into account the feasibility of international travel and ensuring those who represent the Society are not exposed to any unnecessary risk. These meetings do present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows, but this has to be balanced against the other logistical factors. The possibility of linking virtually with previous satellite partners may be explored, but potential online fatigue versus the value of in-person meetings will be factored into any decision.

A financial appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society. The Society does not cover any of the speaker expenses; these costs must be met by the host societies or personally.

Marketing Society activities and '*Cancer Imaging*' remain a priority; electronic means and social media are used to enhance communication with members and the wider international community with an interest in oncological imaging. Developing further membership benefits will be important to maintain and increase membership numbers, and assessment of options presented by the shift to online education. Google analytics of traffic to the ICIS website permits review of activity and the number of members is monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion.

Risks

The introduction of the risk register has enabled regular review by the Executive Board of any potential risk the Society may face, with any such risks reported to the Trustees. Establishing ways to generate additional income streams and promoting the Society worldwide remain a top priority. Proposed developments will be reviewed to ensure that the perceived benefits would outweigh the possible risk to the Society, which needs to maintain a viable, modern, robust structure from which to operate and develop bearing in mind any financial implications or impact on Society reserves.

The sudden global increase of online educational activity in a very competitive virtual environment poses a new challenge and risk to the Society. Whilst migrating activity to online delivery, it is important that the Society's reputation is maintained as a provider of high-quality education on oncological imaging, with articles published in '*Cancer Imaging*' supporting retention of the journal's international standing amongst other journals providing sound research articles and reviews. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series. The financial implications to the Society of any proposed Satellite meetings are carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of Cancer Imaging will be kept under regular review.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

The Trustees also take into consideration potential disasters such as floods, fires, earthquakes, volcanoes, international instability and terrorism that could affect plans for Society teaching courses, particularly those planned as in-person events. The risk posed by infectious diseases remains under stringent review in the light of ongoing international instabilities posed by the COVID-19 pandemic. This will be monitored closely to ensure any potential risk to the Society is assessed in detail and precautions taken as necessary. The Executive Board will continue to keep all these risks under review and report to the Trustees. The city and venue for the Annual Teaching Course is chosen carefully and where possible, a break clause is included in the venue contract to mitigate these potential risks. Insurance is reviewed every year.

By order of the Board on 11 September 2022



Trevor Pereira
Secretary

**INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28th February 2022 set out on pages 11 to 16.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Paul Newton FCA
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date: 21 September 2022

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account) FOR THE YEAR ENDED 28TH FEBRUARY 2022

	<i>Note</i>	<i>Unrestricted 2022 £</i>	<i>Unrestricted 2021 £</i>
Income from			
<i>Charitable activities</i>			
Conference sponsorship and funding		102,489	37,848
Revenue from conference delegates		45,054	-
Membership income		17,317	20,686
ICIS Interactives		34,102	36,674
Journal income		13,423	17,039
Other income		-	397
Interest receivable		447	2,825
Total income		<u>212,832</u>	<u>115,469</u>
Expenditure on			
<i>Charitable activities</i>			
Conference costs		20,239	5,868
Design, production and advertising		3,233	1,051
Administration			
- Data Manager		9,557	13,018
- Events & Marketing, and General Manager	6	70,214	67,829
- Other		2,500	70
Pension Scheme		310	310
Travel and accommodation		4,793	104
Printing		6,919	4,760
Bank charges and credit card charges		2,106	997
Gifts and donations		174	-
Insurance		1,111	-
Accreditations		761	-
Postage/delivery charges		1,251	462
Telephone		115	65
Depreciation		270	306
Software expenses		1,863	921
IT support		-	1,250
Rent		2,114	988
Miscellaneous		561	701
Licenses and Permits		95	137
Books and Publications		-	26
Subscriptions		13	13
Accounting		34,436	33,997
Consultancy Fee		-	5,186
Governance cost: Independent Examiners fees		2,079	1,968
Foreign exchange losses/(gains)		9,116	(876)
Total expenditure		<u>173,830</u>	<u>139,151</u>
Net income / movement in funds		39,002	(23,682)
Reconciliation of funds			
Unrestricted fund balance brought forward		<u>319,546</u>	<u>343,228</u>
Unrestricted fund balance carried forward		<u>358,548</u>	<u>319,546</u>

The notes on pages 13 to 16 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET AS AT 28TH FEBRUARY 2022

		2022		2021	
	Note	£	£	£	£
Fixed assets					
Tangible fixed assets	2		808		1,078
Current assets					
Debtors	3	162,748		17,836	
Cash at bank and in hand		<u>358,396</u>		<u>366,269</u>	
		521,144		384,105	
Creditors: Amounts falling due within one year	4	<u>163,404</u>		<u>65,637</u>	
Net current assets			<u>357,740</u>		<u>318,468</u>
Total Net assets less current liabilities			<u>358,548</u>		<u>319,546</u>
Unrestricted Funds	5		<u>358,548</u>		<u>319,546</u>

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2022 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 11 September 2022 and signed on their behalf by:


Prof. Anwar Padhani
Trustee


Prof. Dow Mu Koh
Trustee

Company Registration number: 03908709

The notes on pages 13 to 16 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2022

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guarantee registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 TANGIBLE FIXED ASSETS

	Computer equipment £	Total £
Cost		
As at 1st March 2021	1,150	1,150
Additions	-	-
Disposals	-	-
As at 28th February 2022	<u>1,150</u>	<u>1,150</u>
Depreciation		
As at 1st March 2021	72	72
Charge for year	270	270
Disposals	-	-
As at 28th February 2022	<u>342</u>	<u>342</u>
Net book value		
As at 28th February 2022	<u>808</u>	<u>808</u>
As at 29th February 2021	<u>1,078</u>	<u>1,078</u>

3 DEBTORS

	2022 £	2021 £
Trade debtors	149,658	2,131
Prepayments and accrued income	<u>13,090</u>	<u>15,705</u>
	<u>162,748</u>	<u>17,836</u>

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

4 CREDITORS

	2022 £	2021 £
Trade creditors	765	283
Accruals and deferred income	<u>162,639</u>	<u>65,354</u>
	<u>163,404</u>	<u>65,637</u>

5 MOVEMENT ON FUNDS

	At 1 st March 2021 £	Total Income £	Total Expenditure £	At 28 th February 2022 £
Unrestricted Funds				
General Fund	<u>319,546</u>	<u>212,832</u>	<u>(173,830)</u>	<u>358,548</u>

	At 1 st March 2020 £	Total Income £	Total Expenditure £	At 29 th February 2021 £
Unrestricted Funds				
General Fund	<u>343,228</u>	<u>115,469</u>	<u>(139,151)</u>	<u>319,546</u>

6 STAFF COSTS

	2022 £	2021 £
Salaries	65,949	63,913
Pension	1,604	1,295
Social security	<u>2,661</u>	<u>2,621</u>
	<u>70,214</u>	<u>67,829</u>
Average no. staff	<u>2</u>	<u>2</u>

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £46,014 (2021: £41,198). There were no other related party transactions in the year.

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2022 (continued)

7 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2021: none). Expenses incurred on behalf of the Society and reimbursed to trustees during the year to 28th February 2022 amounted to £nil (2021: £nil).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

8 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.